What is Damora Therapeutics, Inc.'s (DMRA) StockRank?

MoatMap's StockRank for Damora Therapeutics, Inc. (DMRA) is 20/100, with a Sell signal. This is a composite score combining Quality (36), Value (26), and Momentum (40) factor ranks across MoatMap's 20,000+ stock universe.

Does Damora Therapeutics, Inc. have an economic moat?

Damora Therapeutics, Inc. (DMRA) has a Quality factor score of 36/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Damora Therapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for Damora Therapeutics, Inc. (DMRA) is Sell, based on a StockRank of 20/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Damora Therapeutics, Inc. in?

Damora Therapeutics, Inc. (DMRA) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.

View Deep Dive

DMRA

Sell

Damora Therapeutics, Inc. · Healthcare · United States · $1.8B · Avg Vol: $10M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-99.7%

D/E

0.0x

Dividend %

—

COMPANY DESCRIPTION

Damora Therapeutics, Inc. is a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for treating various diseases. Its competitive strength derives from its proprietary scientific platforms, intellectual property portfolio, and specialized research capabilities. As a clinical-stage biotech firm, its value is significantly tied to the progress and successful outcomes of its drug pipeline through clinical trials and regulatory approvals.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM
Revenue	0	0	0	0	—	—
EPS	-1.01	-0.64	-0.40	-0.10	—	-0.26
Shares	61.6M	61.6M	61.6M	61.6M	0.0%	61.7M
Debt	0.8M	0.2M	73.0K	68.0K	-56.1%	—
Equity	61.8M	32.3M	15.8M	240.4M	57.3%	—
Op CF	-42.9M	-36.9M	-18.6M	-6.7M	—	-44.5M
Inv CF	12.4M	22.3M	11.7M	-17.4M	—	—
Fin CF	0.5M	2.9M	0	266.8M	—	—

Loading 1Y...

PRICE (1Y)-12.1%

SMA 50SMA 200

$29.00

RSI (14)

47.0

52W High

$38.33

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

-99.4%6.8

ROE

-99.7%10.2

GP/Assets

—N/A

Op. Margin

0.0%40.1

FCF/Assets

-3.3%38.5

Piotroski

440.0

Int. Cover

—N/A

D/E Ratio

0.00x95.1

Current Ratio

19.73x95.8

Value

P/E (TTM)

—N/A

EV/EBITDA

-15.2x25.0

P/FCF

—N/A

P/B

4.9x29.3

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

76%58.4

RS 6M

-15%49.5

SMA 50/200

1.12x80.3

EPS Rev 4W

-3.1%18.7

EPS Rev 12W

-1.8%25.0

EPS Improve

-724%0.6

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$1.8B

P/E (Forward)

-14.2x

Gross Margin

—

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DMRA are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
DMRA	Damora Therapeutics, Inc.(you)	$1.8B	20	Sell
TSHA	Taysha Gene Therapies, Inc.	$1.9B	17	Strong Sell
INBX	Inhibrx Biosciences, Inc.	$1.8B	16	Strong Sell
PVLA	Palvella Therapeutics, Inc.	$2.2B	19	Strong Sell
ABSI	Absci Corporation	$1.5B	18	Strong Sell
OCUL	Ocular Therapeutix, Inc.	$2.3B	19	Strong Sell
STOK	Stoke Therapeutics, Inc.	$2.0B	16	Strong Sell
VOR	Vor Biopharma Inc.	$1.3B	21	Sell
NVAX	Novavax, Inc.	$1.5B	16	Strong Sell
REPL	Replimune Group, Inc.	$1.5B	23	Sell

Peer medians: ROE -25.6% · P/E 29.5x · Gross margin 58.7%

Damora Therapeutics, Inc. (DMRA): Stock Score Summary

Damora Therapeutics, Inc. (DMRA) has a MoatMap StockRank of 20/100 based on Quality (36/100), Value (26/100), and Momentum (40/100) factor scores. The current signal is SELL.

Key Financial Metrics

Price	$29.00
Market Cap	$1.8B
P/E (Forward)	-14.18
Price/Book	4.86
Return on Equity	-99.7%
Return on Invested Capital	-99.4%
Debt/Equity	0.00x
Operating Margin	0.0%
Free Cash Flow	$-9M

Damora Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Damora Therapeutics, Inc.’s (DMRA) StockRank?: MoatMap’s StockRank for Damora Therapeutics, Inc. (DMRA) is 20/100, with a Sell signal. It is a composite of Quality (36), Value (26), and Momentum (40) factor ranks across MoatMap’s 20,000+ stock universe.
Does Damora Therapeutics, Inc. have an economic moat?: Damora Therapeutics, Inc. (DMRA) has a Quality factor score of 36/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Damora Therapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for Damora Therapeutics, Inc. (DMRA) is Sell, based on a StockRank of 20/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Damora Therapeutics, Inc. in?: Damora Therapeutics, Inc. (DMRA) operates in the Healthcare sector, specifically the Biotechnology industry (United States).